Start-up fighting gum disease closes $14m round

Denteric

 

CSL-backed biotech company Denteric has closed a $14 million funding round, enabling it to develop a vaccine for a gum disease that affects one in three adults globally, with a human clinical trial expected within three years.

The funding round was led by the¬†Medical Research Commercialisation Fund’s Biomedical Translation Fund (BTF), managed by Brandon Capital Partners,¬†with participation from CSL and the University of Melbourne.

Denteric is a newly formed spinout from the federal government’s Oral Health Co-operative Centre Program (CRC), based at the University of Melbourne.

Read the full article on the Australian Financial Review website.